Adding ultrasound to standard mammography tests in breast screening could result in improved rates of detection for breast cancer in women in Japan, according to a new study published in The Lancet.
Scientists have discovered a new gene linked to an increased risk of bowel cancer recurrence and shortened survival, reveals research in the journal Gut.
The use of superlatives to describe cancer drugs in news articles as “breakthrough,” “revolutionary,” “miracle” or in other grandiose terms is common, even when drugs are not yet approved, have no clinical data or do not yet show overall survival benefits, according to an article in JAMA Oncology.
Among patients with stage II or III rectal cancer, the use of laparoscopic resection compared with open resection fails to meet the criterion for non-inferiority for pathologic outcomes, according to research published in JAMA.
High circulating levels of cardiovascular hormones/peptides in cancer patients are linked to shorter survival, regardless of disease type and stage of progression, reveals research published online in the journal Heart.
Leading primary care professionals and cancer experts warned at the Royal College of General Practitioners (RCGP) annual congress in Glasgow last weekend (October 1-3) that GPs will not be able to cope with the rising demand for cancer care in high-income countries — predicted to double within the next 15 years.
A new study of alcohol use in countries of all income levels shows that current use increases the risk of alcohol-related cancers and injury, with no reduction in risk of mortality or cardiovascular disease overall.
In prostate brachytherapy, the radiation source is placed close to the tumour, Gary Culliton reports in his latest Clinical Update. In essence, brachytherapy is the oldest form of radiation treatment and the technique now used in Ireland was pioneered 40 years ago in the American north west.
Abiraterone acetate is now reimbursed on the high-tech drug scheme for men with metastatic castration-resistant prostate cancer (mCRPC) post-androgen deprivation therapy (ADT).
“It is known that men who have prostate cancer are more likely to die of their disease if they are overweight or obese than if they are of a healthy weight,” according to Dr Stephen Finn, Associate Professor in Histopathology and Morbid Anatomy in Trinity College Dublin and Consultant Pathologist at St James’s Hospital.